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Summary  
Many mechanisms of cisplatin resistance have been proposed from studies of cellular 
models of resistance including changes in cellular drug accumulation, detoxification of 
the drug, inhibition of apoptosis and repair of the DNA adducts. A series of resistant 
models were developed from CCRF-CEM leukaemia cells with increasing doses of 
cisplatin from 100 ng/ml. This produced increasing resistance up to 7-fold with a 
treatment dose of 1.6 µg/ml. Cisplatin resistance in these cells correlated with increases in 
the antioxidant glutathione, yet treatment with buthionine sulphoximine, an inhibitor of 
glutathione synthesis, had no effect on resistance, suggesting that the increase in 
glutathione was not directly involved in cisplatin resistance. Two models were developed 
from H69 SCLC cells, H69-CP and H69CIS200 using 100 ng/ml or 200 ng/ml cisplatin 
respectively. Both cell models were 2-4 fold resistant to cisplatin, and have decreased 
expression of p21 which may increase the cell’s ability to progress through the cell cycle 
in the presence of DNA damage. Both the H69-CP and H69CIS200 cells showed no 
decrease in cellular cisplatin accumulation. However, the H69-CP cells have increased 
levels of cellular glutathione and are cross resistant to radiation whereas the H69CIS200 
cells have neither of these changes. This suggests that increases in glutathione may 
contribute to cross-resistance to other drugs and radiation, but not directly to cisplatin 
resistance. There are multiple resistance mechanisms induced by cisplatin treatment, even 
in the same cell type. How then should cisplatin-resistant cancers be treated? Cisplatin-
resistant cell lines are often more sensitive to another chemotherapeutic drug paclitaxel 
(H69CIS200), or are able to be sensitised to cisplatin with paclitaxel pre-treatment (H69-
CP). The understanding of this sensitisation by paclitaxel using cell models of cisplatin 
resistance will lead to improvements in the clinical treatment of cisplatin resistant 
tumours. 
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Introduction 
Cisplatin has been used in the treatment of cancer for over 30 years, and is highly 
successful for many cancers, including testicular, ovarian and lung cancer. Upon entering 
the cell, cisplatin becomes positively charged, and so is able to interact with nucleophilic 
molecules including DNA, RNA and proteins. Cytotoxicity is believed mainly due to 
interaction with DNA, forming inter- and intra-strand adducts, hindering both RNA 
transcription and DNA replication, leading to cell cycle arrest and apoptosis. Inevitably, 
the use of cisplatin is limited by the development of drug resistance. Numerous cellular 
mechanisms potentially contributing to clinical cisplatin resistance have been proposed 
(1,2) including changes in cellular drug accumulation, detoxification of the drug, 
inhibition of apoptosis and repair of the DNA adducts, as summarised in Fig. 1. 
Understanding these mechanisms and their role in resistance is important for the 
continued success of cancer treatment.  
 
Cellular Models of Cisplatin Resistance 
We have developed several cellular models to attempt to understand the cellular 
adaptations underlying cisplatin resistance mechanisms, and potential strategies to 
reverse this resistance. Small cell lung cancer (SCLC) is an aggressive form of lung 
disease, with treatment involving combination chemotherapy including cisplatin.  While 
this produces 90% response in patients, relapse is rapid with patients developing resistant 
disease.  We have treated H69 SCLC cells with 100 ng/ml cisplatin, to produce the H69-
CP (3) or 200 ng/ml cisplatin to obtain the H69CIS200 cells (4). These doses are below 
an IC50 for cisplatin and are within the range achieved in the clinical use of cisplatin. The 
cells were 2- to 4-fold resistant to cisplatin, but there was no decreased drug 
accumulation.  To further identify molecular changes resulting from low, non-toxic doses 
of cisplatin, the model CCRF-CEM leukaemia cell was treated for 3-4 days with 
increasing doses of cisplatin from 100 ng/ml, a dose well below the IC50 for cisplatin 
(540 ± 30 ng/ml) for these cells. This produced a series of cells with increasing cisplatin 
resistance up to 7-fold resistance with a treatment dose of 1.6 µg/ml, after which 
resistance, as determined in a 4-day cytotoxicity assay, decreased (Figure 2).  Resistance 
was associated with decreased cisplatin accumulation, although, there were no changes in 
expression of the multidrug transport protein MRP2 which transports cisplatin conjugated 
to glutathione to explain the decreased intracellular drug as increased drug efflux (5). 
 
Detoxification mechanisms in cisplatin resistance 
Cisplatin is very reactive towards the cellular antioxidant glutathione, readily forming 
complexes. Resistance in the CEM cells reflected changes in glutathione (Figure 2).  
However, treatment of these cells with buthionine sulphoximine (BSO), an inhibitor of 
glutathione synthesis, had no effect on cellular resistance.  This suggests that although a 
cellular response to cisplatin treatment was to increase their glutathione levels, this was 
not directly involved in cisplatin resistance. Glutathione changes have frequently been 
reported in cells treated with cisplatin, and may contribute to cross-resistance to other 
drugs and radiation, but not necessarily directly to cisplatin resistance. This proposal is 
supported by the SCLC cells which, although 2 to 4-fold resistant to cisplatin, the H69-
CP cells had increased glutathione and cross-resistance to radiation while the H69CIS200 
cells had no change in glutathione and were not radiation resistant.  This is also supported 
by the fact that radiation resistant H69 cells with increased glutathione are highly 
resistant to cisplatin (6). 
 
However, glutathione is not the only thiol cellular redox system, and changes in the 
thioredoxin antioxidant system, thioredoxin reductase and thioredoxin, are also reported 
to confer cisplatin resistance (7). Increased thioredoxin reductase occurred in the 
cisplatin-resistant CEM cells, leading to cross- resistance to the thioredoxin reductase 
inhibitor auranofin, a gold compound clinically used as an antirheumatic drug.  This 
contrasts a recent report suggesting auranofin induces apoptosis in cisplatin resistant 
ovarian cancer cells, and so may be suitable to treat cisplatin resistant tumours (8). Again, 
the involvement of redox systems in cisplatin resistance is variable and may be dependent 
on cell type. 
 
Cisplatin resistance and the cell cycle 
In the CEM series of cisplatin-resistant cells, at higher levels of drug treatment the cells 
do not appear to be resistant as judged in a 4-day cytotoxicity assay.  This is because 
cisplatin treatment causes the cells to stop growing.  On removal of the drug, the cells 
then proliferate rapidly.  While this resistance mechanism occurred at higher drug doses 
in the CEM cells, a similar response to cisplatin was evident after treatment with low 
levels of drug in the H69CIS200 cells (4), where cells rapidly grew on removal of drug. 
The contrast in resistant mechanisms developed in the H69CIS200 and H69-CP cells 
illustrates the diversity of mechanisms which may occur using similar treatment 
strategies even in the same cell line.  
 
As well as alterations in the cell cycle allowing rapid proliferation post drug treatment, 
the H69CIS200 cells also have several chromosomal rearrangements which are not 
associated with the resistant phenotype, suggesting an increase in genomic instability in 
the resistant cell lines (9). We hypothesise that there is a deregulation between the cell 
cycle and DNA repair in the H69CIS200 cells allowing proliferation in the presence of 
DNA damage which has created an increase in genomic instability. The cellular response 
to DNA damage as a result of cisplatin treatment would be induction of p53, causing cells 
to arrest, by regulating the expression of cyclins and cyclin-dependent kinases. Cisplatin 
however does not induce the cyclin-dependent kinase-inhibitor p21 in 2780CP cisplatin 
resistant cells, supporting the disruption of the normal response pathway in resistant cells 
(10). Both the H69CIS200 cells and the H69-CP cells have decreased p21 expression, 
which may increase the cell’s ability to progress through the cell cycle despite the 
presence of DNA damage. This not only provides a resistance mechanism, but will 
contribute to the genomic instability of the cells which in turn will increase the mutagenic 
potential of the cells in response to further drug treatment. 
 DNA Repair Mechanisms 
Since the major effect of cisplatin is the formation of DNA adducts, increased DNA 
repair is a potential resistance mechanism. Nucleotide excision repair (NER) mainly 
repairs bulky DNA adducts such as those caused by interaction with cisplatin, and 
downregulation of ERCC1, a core protein required for NER, sensitised cells to cisplatin 
(11). We have found that the cisplatin-resistant H69CIS200 cells have no alteration in 
DNA repair capacity compared to the parental H69 cells. However, ERCC1 expression 
decreases in association with the cisplatin-induced cell cycle arrest in both sensitive and 
resistant cells rather than in association with any change in DNA repair. Both increased 
ERCC1 expression (12) and decreased ERCC1 expression (13,14) have been associated 
with sensitivity to cisplatin based combination chemotherapy.  Cisplatin treatment may 
alter the expression of ERCC1 for reasons other than DNA repair. This may explain some 
of the contradictory results examining this gene as a marker for the clinical response to 
cisplatin therapy. The ability to differentiate between these different types of platinum 
resistance in the clinic will improve the choice of salvage chemotherapy in patients with 
cisplatin-resistant cancers. 
 
Conclusions 
It is apparent that there are multiple resistance mechanisms induced by cisplatin 
treatment, and as many of these are linked by the cellular stress response, it is difficult to 
determine which of these is more important in resistance. While many mechanisms have 
been identified, there is no consistent response, even in the same cell type to treatment 
with cisplatin. The question then is: how to treat cisplatin-resistant tumours. The cell 
models are useful not only for examining the potential of the new platinum drugs being 
developed, but also for looking for combinations of current drugs which may lead to 
improvements in response. A recent report demonstrated that combination of the cell 
cycle specific antagonist gemcitabine with cisplatin was more effective than either drug 
alone.  This combination gave enhanced toxicity in cisplatin resistant cells, suggesting 
that gemcitabine reversed cisplatin resistance (15,16). 
 
Of particular interest are the frequent reports of sensitivity to paclitaxel in cisplatin 
resistant cells.  This was evident in the H69CIS200 cells which were 5-fold more 
sensitive to paclitaxel than the H69 cells.  The other cisplatin resistant cells, although 
cross-resistant to many drugs, were not resistant to paclitaxel. However, treatment of 
these cisplatin resistant cells, but not the H69 cells, with non-cytotoxic doses of paclitaxel 
was able to sensitise the resistant cells not only to cisplatin, but to other drugs, and also to 
radiation (17,18,3) Paclitaxel sensitization occurred after at least a 12 hour pre-treatment 
of the cells, suggesting time is required for this response. Analysis of the protein profile 
of these cells showed that paclitaxel treatment reversed many of the cellular protein 
changes that accompanied the development of resistance (19). This activity of paclitaxel 
was independent of the cell cycle mediated effect of the drug, which suggests other 
signaling pathways are involved (18). Understanding this sensitization of cisplatin 
resistant cells would lead to improved treatment protocols for the treatment of all forms 
of cisplatin resistance, and suggests that while cisplatin resistance is multifactorial, the 
means to overcome resistance may lie in inhibition of one specific signaling pathway.  
Future studies using cell models of cisplatin resistance will lead to an understanding of 
ways to overcome cisplatin resistance and improve the treatment of cisplatin resistant 
tumours. 
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Figure 1. Cisplatin resistance mechanisms. Cisplatin is a neutral complex which on entering the cell becomes positively charged, 
and so able to interact with many molecules including DNA and proteins.  Many mechanisms may contribute to cisplatin 
resistance including reduced uptake, increased efflux, increased detoxification, inhibition of apoptosis, increased ability to 
replicate DNA adducts and increased DNA repair. GS – Glutathione, Pol – Polymerase.
C
is
pl
a t
in
 F
ol
d
 
R
e
si
s t
an
ce
CP
10
0
CP
20
0
CP
40
0
CP
80
0
CP
16
00
CP
32
00
CP
50
00
0
2.5
5.0
7.5
Resistance
0
100
200
CP
10
0
CP
20
0
CP
40
0
CP
80
0
CP
16
00
CP
32
00
CP
50
00
G
lu
ta
th
io
ne
(%
 C
E
M
)
Glutathione
100 200 400 800 1600 3200 5000 ng/mlCEM
Figure 2. Cisplatin Resistance in CEM cells.  CEM cells were treated for 3-4 days with cisplatin, 
commencing with 100 ng/ml.  After 6 treatments, cells were stable to drug treatment and the doses 
increased.  This developed a series of cisplatin-resistant cells.  Cisplatin resistance (fold increase 
relative to the untreated CEM cells) is reflected in cellular glutathione levels. 
